Status:
TERMINATED
A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety
Lead Sponsor:
Pfizer
Conditions:
Obesity
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults
Detailed Description
The CP-945,598 program was terminated on November 3, 2008 due to changing regulatory perspectives on the risk/benefit profile of the CB1 class and likely new regulatory requirements for approval. No s...
Eligibility Criteria
Inclusion
- Obese adults with a body mass index \> or = 30 kg/m2; \> or = to 27 kg/m2 for those with obesity-related comorbidities including hypertension and dyslipidemia
Exclusion
- Pregnancy
- Diabetes
- Adults with serious or unstable current or past medical conditions
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
2536 Patients enrolled
Trial Details
Trial ID
NCT00375401
Start Date
October 1 2006
End Date
January 1 2009
Last Update
November 7 2012
Active Locations (82)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Fairhope, Alabama, United States, 36532
2
Pfizer Investigational Site
Huntsville, Alabama, United States, 35801
3
Pfizer Investigational Site
Mobile, Alabama, United States, 36608
4
Pfizer Investigational Site
La Jolla, California, United States, 92037